Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of GenSci145 in PIK3CA-mutant advanced or metastatic solid tumors
CTR20260297Phase 2Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GenSci145 in Nonhematologic neoplasms, breast cancer, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
GenSci145
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on CTR20260297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260297.